Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1875-1879

  Chen, Guo Qiang ^a   Luo, Jian Bin ^a   Wang, Guang Zhi ^a   Ding, Jin E ^a  

^a The Second Hospital of Longyan   (China)

Author keywords

Association; Meta analysis; Prostate cancer; VEGF

Indexed keywords

VASCULOTROPIN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; PUBLISHING; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUMOR GENE; VEGF GENE;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899100649     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1250-9     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10-29.
3. Bikfalvi A. Angiogenesis and invasion in cancer. Handb Clin Neurol. 2012;104:35-43.
4. Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110:E794-808.
5. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9:498-509.
6. Lin J, Kelly WK. Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am. 2012;39:547-60.
7. Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259-69.
8. Giacca M, Zacchigna S. Vegf gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012;19:622-9.
9. Sfar S, Saad H, Mosbah F, Chouchane L. Synergistic effect and vegf/hsp70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome. Hum Immunol. 2010;71:377-82.
10. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of vegf genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21-8.
11. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the turkish population. Mol Biol Rep. 2008;35:17-22.
12. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 c/t polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374-7.
13. Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572-6.
14. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:972-7.
15. Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, et al. Clinical implication of vascular endothelial growth factor t-460c polymorphism in the risk and progression of prostate cancer. Oncol Rep. 2007;18:1155-63.
16. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
20. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34:1895-9.
21. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943-8.
22. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369-72.
23. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor snps as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8:2496-508.
24. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, et al. Interaction among variant vascular endothelial growth factor (vegf) and its receptor in relation to prostate cancer risk. Prostate. 2010;70:341-52.